Calviri

Calviri is a private, clinical-stage biotech leveraging a novel discovery about a fundamental molecular characteristic of tumors to develop early cancer detection diagnostics and off-the-shelf vaccines. The company's core strategy is a 'One Health' approach, initially targeting the significant unmet need in canine cancer with its first commercial product, StageOne Plus, a multi-cancer diagnostic test, and advancing preventative (VACCS) and therapeutic vaccine trials in dogs. This veterinary focus provides a faster development and regulatory pathway, aiming to generate proof-of-concept, revenue, and data to de-risk subsequent human applications. Calviri is backed by venture funding and grants, positioning it to potentially disrupt oncology by shifting the paradigm from late-stage treatment to early detection and prevention.

Platforms based on the discovery of fundamental molecular signatures (fixation antigens) common to all tumors. Merges biology with semiconductor chip technology for high-throughput analysis to develop multi-cancer early detection diagnostics and off-the-shelf therapeutic/preventative vaccines.

In canine diagnostics, Calviri's StageOne Plus faces limited direct competition for multi-cancer early detection. In the human space, it would compete with giants like Exact Sciences and Grail (Illumina) in diagnostics, and with numerous biotechs in therapeutic cancer vaccines. Its key differentiation is the focus on shared 'fixation antigens' for off-the-shelf vaccines and claimed high Stage 1 sensitivity.